Metastatic Colon Cancer Clinical Trial
Official title:
Non-comparative Prospective Observational Cohort Study Describing the Safety and Efficacy of Aflibercept Administered in Combination With FOLFIRI After Failure Under Oxaliplatin + Anti-EGFR Therapy in the Treatment of Patients With Metastatic Colorectal Cancer in Practice Common
Primary objective
- Evaluate the efficacy in terms of progression-free survival (PFS) of aflibercept in
combination with FOLFIRI in patients treated routinely for metastatic colorectal cancer
(mCRC) after failure of treatment with oxaliplatin + EGFR.
Secondary objective
- Evaluate the efficacy of aflibercept in combination with FOLFIRI on the 2-year overall
survival rate and the objective response rate.
- Evaluate the tolerance profile of aflibercept in combination with FOLFIRI.
- Observational study, national, multicenter, cohort, prospective without
intervention on the therapeutic strategy.•
Inclusion criteria
- All patients expected to be treated with aflibercept in combination with FOLFIRI for a
mCRC, after failure of treatment with oxaliplatin + anti-EGFR on the decision of the
doctor (situation included in the framework of the MA of aflibercept) .
- Age ≥18 years
- Signature of the agreement for the collection of medical and personal data. (Patients
who have received FOLFIRINOX in the first line metastatic are allowed) Note: Failure is
defined as progression during or within 6 months after discontinuation of oxaliplatin
Exclusion criteria :
- Concurrent participation in a clinical trial
- Patients who have previously received anti-VEGF agents and / or aflibercept in one
trial.
- Patients who received FOLFIRI in the first metastatic line.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04186117 -
Development of Clinical and Biological Database in Colorectal Cancer
|
N/A | |
| Completed |
NCT05468892 -
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
|
Phase 2 | |
| Recruiting |
NCT02291744 -
A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT05983367 -
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06180460 -
CALM: Managing Distress in Malignant Brain Cancer
|
N/A | |
| Active, not recruiting |
NCT03251378 -
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04737213 -
SGM-101 in Colorectal Lung Metastases
|
Phase 2 | |
| Recruiting |
NCT05714124 -
Liver Embolization Approaches for Tumor Management
|
||
| Recruiting |
NCT05396807 -
REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients
|
N/A | |
| Active, not recruiting |
NCT02724202 -
Curcumin in Combination With 5FU for Colon Cancer
|
Early Phase 1 | |
| Withdrawn |
NCT03764137 -
Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05848739 -
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06202183 -
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
|
N/A | |
| Withdrawn |
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A | |
| Not yet recruiting |
NCT06358677 -
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT03415126 -
A Study of ASN007 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02834052 -
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06446557 -
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer
|
Phase 3 |